Chong Kun Dang Pharmaceutical종근당
185750 · KOSPI · ₩185750 · 종근당
₩63,100▲ ₩600 (0.96%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩1.7T | ₩1.6T | ₩1.7T | ₩1.5T | ₩1.3T |
| Cost of sales | ₩1.2T | ₩1.1T | ₩1T | ₩946B | ₩848B |
| Gross profit | ₩526B | ₩533B | ₩662B | ₩543B | ₩496B |
| Operating income | ₩81B | ₩99B | ₩247B | ₩110B | ₩95B |
| Net income | ₩78B | ₩111B | ₩214B | ₩80B | ₩42B |
| Net income to shareholders | ₩78B | ₩109B | ₩213B | ₩81B | ₩43B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩1.8T | ₩1.5T | ₩1.4T | ₩1.1T | ₩1T |
| Current assets | ₩1.1T | ₩962B | ₩947B | ₩714B | ₩667B |
| Cash and equivalents | ₩216B | ₩228B | ₩220B | ₩117B | ₩132B |
| Total liabilities | ₩794B | ₩562B | ₩587B | ₩504B | ₩481B |
| Current liabilities | ₩516B | ₩369B | ₩511B | ₩374B | ₩320B |
| Borrowings | ₩358B | ₩182B | ₩212B | ₩234B | ₩234B |
| Total equity | ₩1T | ₩896B | ₩816B | ₩621B | ₩566B |
| Shareholders' equity | ₩1T | ₩894B | ₩816B | ₩622B | ₩566B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩67B | ₩64B | ₩318B | ₩68B | ₩13B |
| Capital spending | ₩141B | ₩38B | −₩41B | −₩45B | −₩48B |
| Free cash flow | −₩74B | ₩26B | ₩277B | ₩23B | −₩35B |
| Dividends paid | ₩14B | ₩13B | ₩12B | −₩11B | −₩11B |
Consolidated where available. Amounts in won.
Also known as: Chong Kun Dang Pharmaceutical / 종근당 / 185750 / KRX:185750
Source: KRX statistical information